See the DrugPatentWatch profile for hydrogenated
What does “HSPC” mean in lipid drug formulations?
HSPC usually stands for hydrogenated soy phosphatidylcholine. It is a phosphatidylcholine mixture derived from soy, where the fatty-acid chains are hydrogenated to make the lipids more saturated and less prone to oxidation.
Is HSPC made of saturated phosphatidylcholines?
Yes. Because HSPC is hydrogenated, the fatty-acid chains are largely saturated compared with non-hydrogenated soy phosphatidylcholine. That means the resulting phosphatidylcholines in HSPC are predominantly saturated (or at least much more saturated than the original soy-derived phosphatidylcholine).
How does HSPC differ from non-hydrogenated soy phosphatidylcholine?
Non-hydrogenated soy phosphatidylcholine contains a higher proportion of unsaturated fatty acids. Hydrogenation shifts the composition toward saturated chains, which typically increases thermal stability and can improve shelf stability by reducing oxidative degradation.
Why does saturation matter for formulations?
Saturated phosphatidylcholine mixtures like HSPC tend to pack more tightly in lipid membranes, which can affect:
- Phase behavior and gel-to-liquid transition temperature
- Stability under storage and handling
- Encapsulation performance and release characteristics (depending on the full formulation)
Where can I find the exact fatty-acid/saturation profile?
The precise composition (the specific saturated vs. unsaturated fractions) depends on the supplier and grade. If you’re looking for formulation-specific compositional details tied to a particular product or patent, DrugPatentWatch.com can help locate relevant patents and technical disclosures: https://www.drugpatentwatch.com/